Engineering organoids-on-chips for drug testing and evaluation

Area of Science:

• Biotechnology
• Regenerative Medicine
• Drug Discovery

Background:

• Traditional preclinical models like 2D cell cultures and animal studies have limitations in accurately predicting human physiological responses.
• Organoids-on-chips represent a significant advancement, integrating stem cell-derived organoids with microfluidic technology.
• This technology aims to create more biomimetic in vitro systems for enhanced drug development.

Purpose of the Study:

• To review the challenges and requirements for effective preclinical drug screening models.
• To highlight the capabilities of organoids-on-chips in replicating human physiology.
• To explore the potential and obstacles in developing advanced organoids-on-chips for drug assessment.

Main Methods:

• Review of current literature on organoids-on-chips in drug screening and safety evaluation.
• Analysis of the features and benefits of organoids-on-chips compared to traditional models.
• Discussion of recent advancements and future directions in the field.

Main Results:

• Organoids-on-chips offer a superior platform for in vitro construction of biomimetic micro-physiological systems.
• This technology authentically replicates human physiology, addressing limitations of conventional drug screening methods.
• Recent studies demonstrate successful applications of organoids-on-chips in drug screening and safety assessments.

Conclusions:

• Organoids-on-chips present a promising avenue for more accurate and efficient drug screening and safety evaluations.
• Further development is needed to enhance the practicality and clinical translation of these sophisticated models.
• Multidisciplinary innovation is key to accelerating the adoption of organoids-on-chips in healthcare and industry.